TC-2216

TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and was researched for the treatment of anxiety and depression.[1] It was unsuccessful as a therapeutic but is still used in pharmacological research as an alpha4beta2-selective antagonist.[2]

TC-2216
Identifiers
  • 8-pyridin-3-yl-1,8-diazaspiro[4.4]nonane
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H17N3
Molar mass203.283 g·mol−1
3D model (JSmol)
  • N1CCCC1(CC2)CN2c3cnccc3
  • InChI=1S/C12H17N3/c1-3-11(9-13-6-1)15-8-5-12(10-15)4-2-7-14-12/h1,3,6,9,14H,2,4-5,7-8,10H2
  • Key:NXIPMBQVNTWEEX-UHFFFAOYSA-N
  (verify)

References
  1. Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
  2. Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, Bencherif M (2008). "TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity". CNS Neuroscience & Therapeutics. 14 (4): 266–77. doi:10.1111/j.1755-5949.2008.00054.x. PMC 6494058. PMID 19040552.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.